Last reviewed · How we verify

Placebo to Reformulated Raltegravir — Competitive Intelligence Brief

Placebo to Reformulated Raltegravir (Placebo to Reformulated Raltegravir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease.

phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Reformulated Raltegravir (Placebo to Reformulated Raltegravir) — Merck Sharp & Dohme LLC. Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo to Reformulated Raltegravir TARGET Placebo to Reformulated Raltegravir Merck Sharp & Dohme LLC phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase
TRUVADA + Raltegravir TRUVADA + Raltegravir Fenway Community Health marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase and HIV integrase
Bictegravir (BIC) Bictegravir (BIC) National Institute of Allergy and Infectious Diseases (NIAID) marketed Integrase strand transfer inhibitor (INSTI) HIV integrase
Dolutegravir/Lamivudine Dolutegravir/Lamivudine Saint Michael's Medical Center marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
ELV/COBI/FTC/TAF ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) HIV integrase, HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF DTG/3TC/ABC + ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
lopinavir/ritonavir and raltegravir lopinavir/ritonavir and raltegravir Saint Michael's Medical Center marketed Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir) HIV protease (lopinavir/ritonavir) and HIV integrase (raltegravir)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

  1. ViiV Healthcare · 12 drugs in this class
  2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
  3. Merck Sharp & Dohme LLC · 5 drugs in this class
  4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
  5. Germans Trias i Pujol Hospital · 1 drug in this class
  6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
  7. ANRS, Emerging Infectious Diseases · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. University of Colorado, Denver · 1 drug in this class
  10. MU-JHU CARE · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Reformulated Raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-reformulated-raltegravir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: